Skip to main content
Have a personal or library account? Click to login
Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay / Determinarea rapidă a apixabanului în plasma umană prin cromatografie de lichide de înaltă performanță cuplată cu spectrometrie de masă în tandem Cover

Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay / Determinarea rapidă a apixabanului în plasma umană prin cromatografie de lichide de înaltă performanță cuplată cu spectrometrie de masă în tandem

Revista Romana de Medicina de Laborator
Volume 23 (2015): Issue 1 (March 2015)
By: ,  ,  ,  ,  ,  ,   and    
Open Access
|Mar 2015
References

References

  1. 1. Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm. 2012;69(13):1113-26. DOI: 10.2146/ajhp110418
    Open DOISearch in Google Scholar
  2. 2. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69-82. DOI: 10.1007/s40262-012-0030-9
    Open DOISearch in Google Scholar
  3. 3. European Medicine Agency, Eliquis: Summary of Product Characteristics. Available at http://www.ema.\europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed October 23rd, 2014.
    Search in Google Scholar
  4. 4. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. DOI: 10.1056/NEJMoa1302507
    Open DOISearch in Google Scholar
  5. 5. Cheng JW, Barillari G. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. J Clin Pharm Ther. 2014;39(2):118-35. DOI: 10.1111/jcpt.12122
    Open DOISearch in Google Scholar
  6. 6. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013 Aug 8;8:CD008980. DOI: 10.1002/14651858.CD008980.pub2
    Open DOISearch in Google Scholar
  7. 7. Bauer KA. Pros and cons of new oral anticoagulants. Management of Thromboembolic Disease. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. DOI: 10.1182/asheducation-2013.1.464
    Open DOISearch in Google Scholar
  8. 8. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology. 2013 Jun;118(6):1466-74. DOI: 10.1097/ ALN.0b013e318289bcba
    Open DOISearch in Google Scholar
  9. 9. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anesthesia and antithrombotic agents: recommendations of the European society of Anaesthesiology. Eur J Anaesthesiol. 2010 Dec;27(12):999-1015. DOI: 10.1097/ EJA.0b013e32833f6f6f
    Open DOISearch in Google Scholar
  10. 10. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb;75(2):476-87. DOI: 10.1111/j.1365-2125.2012.04369.x
    Open DOISearch in Google Scholar
  11. 11. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. DOI: 10.1182/asheducation-2013.1.464
    Open DOISearch in Google Scholar
  12. 12. Brieger D. Anticoagulation: a GP primer on the new oral anticoagulants. Aust Fam Physician. 2014;43(5):254-9.
    Search in Google Scholar
  13. 13. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. [Abstract] Thromb Haemost. 2013;110(2):283-94. DOI: 10.1160/ TH12-12-0898
    Open DOISearch in Google Scholar
  14. 14. Vílchez JA, Gallego P, Lip GYH. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf 2014;5(1):8-20. DOI: 10.1177/2042098613507945
    Open DOISearch in Google Scholar
  15. 15. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complications and emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis. 2013;106(6-7):382-93. DOI: 10.1016/j.acvd.2013.04.009
    Open DOISearch in Google Scholar
  16. 16. Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier F. Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. Biomed Res Int. 2014;2014:385014. DOI: 10.1155/2014/385014
    Open DOISearch in Google Scholar
  17. 17. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013 Jun;35(3):262-8. DOI: 10.1111/ ijlh.12065
    Open DOISearch in Google Scholar
  18. 18. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit. 2014 Oct;36(5):597-605. DOI: 10.1097/ FTD.0000000000000059
    Open DOISearch in Google Scholar
  19. 19. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Nov;100:230-5. DOI: 10.1016/j.jpba.2014.08.011
    Open DOISearch in Google Scholar
  20. 20. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra- performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost. 2014 Oct;12(10):1636-46. DOI: 10.1111/jth.12702
    Open DOISearch in Google Scholar
  21. 21. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 Jan;37(1):74-81. DOI: 10.1124/ dmd.108.023143
    Open DOISearch in Google Scholar
  22. 22. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013 Nov;76(5):776-86. DOI: 10.1111/bcp.12106
    Open DOISearch in Google Scholar
  23. 23. Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013 Dec 6;5:177-84. DOI: 10.2147/CPAA.S51981
    Open DOISearch in Google Scholar
  24. 24. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal. 2013 May 5;78-79:150-3. DOI: 10.1016/j. jpba.2013.02.007
    Search in Google Scholar
  25. 25. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):908-16. DOI: 10.1111/ bcp.12114
    Open DOISearch in Google Scholar
  26. 26. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014 Apr;14(2):147-54. DOI: 10.1007/ s40256-013-0055-y
    Open DOISearch in Google Scholar
  27. 27. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014 Feb;111(2):240-8. DOI: 10.1160/TH13-06-0470
    Open DOISearch in Google Scholar
  28. 28. Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Register. 2001;66.
    Search in Google Scholar
  29. 29. Guidance on the Investigation of Bioavailability and Bioequivalence. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. 2001; CPMP/EWP/QWP/1401/98.
    Search in Google Scholar
  30. 30. Imre S, Vlase L, Muntean DL. Bioanalytical method validation. Rev Romana Med Lab. 2008;10(1):13-21.
    Search in Google Scholar
  31. 31. Guideline on bioanalytical method validation. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). 275542 / 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
    Search in Google Scholar
  32. 32. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). September 2013 http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf
    Search in Google Scholar
DOI: https://doi.org/10.1515/rrlm-2015-0006 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Journal RSS Feed
Language: English, Romanian
Page range: 115 - 125
Submitted on: Dec 6, 2014
Accepted on: Feb 16, 2015
Published on: Mar 25, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Keywords:
apixaban;LC-MS/MS;therapeutic drug monitoring
Related subjects:
Life sciences,
Molecular biology

© 2015 Ioan Țilea, Daniela Saveta Popa, Timea Szakács Xantus, Daniela Primejdie, Bianca Grigorescu, Brîndușa Țilea, Andreea Elena Bocicor, Andreea Varga, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 23 (2015): Issue 1 (March 2015)
Previous article
Next article